Table 3.

Comparisons of outcomes for the ACR Pedi 70 criteria and inactive disease according to the clinical JADAS‐10 at 12 months in each CTP group^*

	ACR Pedi 70 (PS‐weighted, imputed)	Inactive disease according to the clinical JADAS‐10 (PS‐weighted, imputed)
Percentage with outcome in each group (95% CI)
Step‐up CTP	61.5 (53.5, 69.5)	42.8 (35.7, 49.9)
Early combination CTP	80.7 (69.5, 91.9)	58.8 (46.6, 71.1)
Biologic first CTP	63.6 (37.7, 89.5)	47.1 (25.0, 69.3)
Difference in percentage between groups (95% CI)
Biologic first CTP versus step‐up CTP	2.1 (−25.2, 29.4)	4.3 (−18.8, 27.5)
Early combination CTP versus step‐up CTP	19.2 (5.0, 33.4)†	16.0 (1.8, 30.2)‡
Biologic first CTP versus early combination CTP	−17.1 (−45.3, 11.1)	−11.7 (−36.7, 13.3)

^*For the comparison of propensity score (PS)–weighted percentages between groups, accounting for multiple imputation, P = 0.02 for the American College of Rheumatology (ACR) Pediatric 70 (Pedi 70) criteria; P = 0.05 for inactive disease according to the clinical Juvenile Arthritis Disease Activity Score in 10 joints (JADAS‐10), by the Wald test. CTP = consensus treatment plan; 95% CI = 95% confidence interval.

^† P = 0.0082.

^‡ P = 0.0270.